Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03483103 · OUTCOME

Change From Baseline of Hematology Laboratory Results: Hemoglobin

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) · Source last updated 2023-12-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
g/L
Interval / dispersion
Standard Deviation
Time frame
Baseline and Day 29

What was measured

Change from baseline in Hematology laboratory analysis. Includes Hemoglobin. Baseline is the last observation collected prior to or on the date of product infusion.

Analysis population: All participants who received at least one JCAR017 infusion evaluable for hematology laboratory tests

Groups in this outcome

Lisocabtagene Maraleucel (JCAR017)

Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Lisocabtagene Maraleucel (JCAR017)59

Reported measurements

Source class 1
Values in g/L · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Lisocabtagene Maraleucel (JCAR017)1.910.05Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        10.05
        value
        1.9
denoms
  1. counts
    1. group Id
      OG000
      value
      59
    units
    Participants
description
Change from baseline in Hematology laboratory analysis. Includes Hemoglobin. Baseline is the last observation collected prior to or on the date of product infusion.
dispersion Type
Standard Deviation
groups
  1. description
    Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.
    id
    OG000
    title
    Lisocabtagene Maraleucel (JCAR017)
param Type
MEAN
population Description
All participants who received at least one JCAR017 infusion evaluable for hematology laboratory tests
reporting Status
POSTED
time Frame
Baseline and Day 29
title
Change From Baseline of Hematology Laboratory Results: Hemoglobin
type
SECONDARY
unit Of Measure
g/L

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice